Exelixis Inc Stock-Based Compensation
Exelixis Inc (EXEL) reported Stock-Based Compensation of $61.61 million for the 6-month period ending 2026-07-03, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-05
- Exelixis Inc share-based payment arrangement, noncash expense for the quarter ending 2026-07-03 was $32.56M, a 9.73% decline year-over-year.
- Exelixis Inc share-based payment arrangement, noncash expense for the quarter ending 2026-04-03 was $29.05M, a 12.03% increase year-over-year.
- Exelixis Inc share-based payment arrangement, noncash expense for the quarter ending 2026-01-02 was $20.10M, a 23.72% decline year-over-year.
- Exelixis Inc share-based payment arrangement, noncash expense for the quarter ending 2025-10-03 was $30.89M, a 34.15% increase year-over-year.
- Exelixis Inc share-based payment arrangement, noncash expense for fiscal 2026 was $112.98M, a 20.40% increase from fiscal 2025.
- Exelixis Inc share-based payment arrangement, noncash expense for fiscal 2025 was $93.84M, a 11.76% decline from fiscal 2023.
- Exelixis Inc share-based payment arrangement, noncash expense for fiscal 2023 was $106.34M, a 1.14% decline from fiscal 2022.
- Exelixis Inc share-based payment arrangement, noncash expense for fiscal 2022 was $107.57M, a 10.22% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-07-03 | $32.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $61.61M 10-Q · filed 2026-08-05 | $81.71M derived: sum of 3 quarters · filed 2026-08-05 | $112.59M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-04-03 | $29.05M 10-Q · filed 2026-05-05 | $49.15M derived: sum of 2 quarters · filed 2026-05-05 | $80.03M derived: sum of 3 quarters · filed 2026-05-05 | $116.10M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-01-02 | $20.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $50.98M derived: sum of 2 quarters · filed 2026-02-10 | $87.05M derived: sum of 3 quarters · filed 2026-08-05 | $112.98M 10-K · filed 2026-02-10 |
| 2025-10-03 | $30.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $66.96M derived: sum of 2 quarters · filed 2026-08-05 | $92.89M 10-Q · filed 2025-11-04 | $119.23M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-07-04 | $36.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $62.00M 10-Q · filed 2026-08-05 | $88.35M derived: sum of 3 quarters · filed 2026-08-05 | $111.37M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-04-04 | $25.93M 10-Q · filed 2026-05-05 | $52.28M derived: sum of 2 quarters · filed 2026-05-05 | $75.30M derived: sum of 3 quarters · filed 2026-05-05 | $100.65M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-01-03 | $26.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $49.37M derived: sum of 2 quarters · filed 2026-02-10 | $74.72M derived: sum of 3 quarters · filed 2026-02-10 | $93.84M 10-K · filed 2026-02-10 |
| 2024-09-27 | $23.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $48.38M derived: sum of 2 quarters · filed 2025-11-04 | $67.49M 10-Q · filed 2025-11-04 | $91.80M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-28 | $25.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-28 | $44.47M 10-Q · filed 2025-07-28 | $68.77M derived: sum of 3 quarters · filed 2026-02-10 | $109.25M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-29 | $19.11M 10-Q · filed 2025-05-13 | $43.42M derived: sum of 2 quarters · filed 2026-02-10 | $83.90M derived: sum of 3 quarters · filed 2026-02-10 | $108.80M derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-29 | $24.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $64.78M derived: sum of 2 quarters · filed 2026-02-10 | $89.68M derived: sum of 3 quarters · filed 2026-02-10 | $106.34M 10-K · filed 2026-02-10 |
| 2023-09-29 | $40.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | $65.38M derived: sum of 2 quarters · filed 2024-10-29 | $82.04M 10-Q · filed 2024-10-29 | $107.89M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $24.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $41.56M 10-Q · filed 2024-08-06 | $67.42M derived: sum of 3 quarters · filed 2025-02-11 | $104.75M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $16.66M 10-Q · filed 2024-04-30 | $42.52M derived: sum of 2 quarters · filed 2025-02-11 | $79.85M derived: sum of 3 quarters · filed 2025-02-11 | $104.48M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-30 | $25.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $63.19M derived: sum of 2 quarters · filed 2025-02-11 | $87.81M derived: sum of 3 quarters · filed 2025-02-11 | $107.57M 10-K · filed 2025-02-11 |
| 2022-09-30 | $37.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $61.96M derived: sum of 2 quarters · filed 2023-11-01 | $81.72M 10-Q · filed 2023-11-01 | $104.88M derived: sum of 4 quarters · filed 2024-02-06 |
| 2022-07-01 | $24.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $44.38M 10-Q · filed 2023-08-01 | $67.55M derived: sum of 3 quarters · filed 2024-02-06 | $101.51M derived: sum of 4 quarters · filed 2024-02-06 |
| 2022-04-01 | $19.76M 10-Q · filed 2023-05-09 | $42.92M derived: sum of 2 quarters · filed 2024-02-06 | $76.89M derived: sum of 3 quarters · filed 2024-02-06 | $104.93M derived: sum of 4 quarters · filed 2024-02-06 |
| 2021-12-31 | $23.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-06 | $57.13M derived: sum of 2 quarters · filed 2024-02-06 | $85.17M derived: sum of 3 quarters · filed 2024-02-06 | $119.82M 10-K · filed 2024-02-06 |
| 2021-10-01 | $33.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $62.00M derived: sum of 2 quarters · filed 2022-11-01 | $96.65M 10-Q · filed 2022-11-01 | $115.93M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-07-02 | $28.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $62.69M 10-Q · filed 2022-08-09 | $81.97M derived: sum of 3 quarters · filed 2023-02-07 | $137.62M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-04-02 | $34.65M 10-Q · filed 2022-05-10 | $53.93M derived: sum of 2 quarters · filed 2023-02-07 | $109.59M derived: sum of 3 quarters · filed 2023-02-07 | $125.74M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-01-01 | $19.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $74.93M derived: sum of 2 quarters · filed 2023-02-07 | $91.09M derived: sum of 3 quarters · filed 2023-02-07 | $105.07M 10-K · filed 2023-02-07 |
| 2020-10-02 | $55.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $71.81M derived: sum of 2 quarters · filed 2021-11-02 | $85.79M 10-Q · filed 2021-11-02 | $101.65M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-07-03 | $16.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $30.14M 10-Q · filed 2021-08-05 | $45.99M derived: sum of 3 quarters · filed 2022-02-18 | $59.13M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-04-03 | $13.98M 10-Q · filed 2021-05-06 | $29.84M derived: sum of 2 quarters · filed 2022-02-18 | $42.98M derived: sum of 3 quarters · filed 2022-02-18 | $58.05M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-01-03 | $15.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $28.99M derived: sum of 2 quarters · filed 2022-02-18 | $44.07M derived: sum of 3 quarters · filed 2022-02-18 | $56.60M 10-K · filed 2022-02-18 |
| 2019-09-27 | $13.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $28.22M derived: sum of 2 quarters · filed 2020-11-05 | $40.75M 10-Q · filed 2020-11-05 | $53.04M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-28 | $15.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $27.61M 10-Q · filed 2020-08-06 | $39.90M derived: sum of 3 quarters · filed 2020-08-06 | $49.65M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-29 | $12.53M 10-Q · filed 2020-05-05 | $24.82M derived: sum of 2 quarters · filed 2020-05-05 | $34.57M derived: sum of 3 quarters · filed 2020-05-05 | $43.85M derived: sum of 4 quarters · filed 2020-05-05 |
| 2018-12-28 | $12.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $22.04M derived: sum of 2 quarters · filed 2020-02-25 | $31.32M derived: sum of 3 quarters · filed 2020-02-25 | $40.63M 10-K · filed 2021-02-11 |
| 2018-09-28 | $9.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $19.02M derived: sum of 2 quarters · filed 2019-10-30 | $28.33M 10-Q · filed 2019-10-30 | $37.24M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-29 | $9.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $18.59M 10-Q · filed 2019-07-31 | $27.50M derived: sum of 3 quarters · filed 2020-02-25 | $32.79M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-30 | $9.30M 10-Q · filed 2019-05-01 | $18.21M derived: sum of 2 quarters · filed 2020-02-25 | $23.50M derived: sum of 3 quarters · filed 2020-02-25 | |
| 2017-12-29 | $8.91M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $14.20M derived: sum of 2 quarters · filed 2020-02-25 | $23.94M 10-K · filed 2020-02-25 | |
| 2017-09-30 | $5.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $15.03M 10-Q · filed 2017-11-01 | ||
| 2017-09-29 | $5.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $10.32M derived: sum of 2 quarters · filed 2018-11-01 | $15.03M 10-Q · filed 2018-11-01 | $19.59M derived: sum of 4 quarters · filed 2018-11-01 |
| 2017-06-30 | $5.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $9.74M 10-Q · filed 2017-08-02 | $14.31M derived: sum of 3 quarters · filed 2018-05-02 | $17.91M derived: sum of 4 quarters · filed 2018-05-02 |
| 2017-03-31 | $4.71M 10-Q · filed 2017-05-01 | $9.28M derived: sum of 2 quarters · filed 2018-05-02 | $12.88M derived: sum of 3 quarters · filed 2018-05-02 | $16.44M derived: sum of 4 quarters · filed 2018-05-02 |
| 2016-12-31 | $4.57M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $8.17M derived: sum of 2 quarters · filed 2017-11-01 | $11.73M derived: sum of 3 quarters · filed 2017-11-01 | $22.91M 10-K · filed 2017-02-27 |
| 2016-12-30 | $22.91M 10-K · filed 2019-02-22 | |||
| 2016-09-30 | $3.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $7.16M derived: sum of 2 quarters · filed 2017-11-01 | $18.35M 10-Q · filed 2017-11-01 | $24.90M derived: sum of 4 quarters · filed 2017-11-01 |
| 2016-06-30 | $3.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $14.74M 10-Q · filed 2017-08-02 | $21.30M derived: sum of 3 quarters · filed 2017-08-02 | $33.33M derived: sum of 4 quarters · filed 2017-08-02 |
| 2016-03-31 | $11.19M 10-Q · filed 2017-05-01 | $17.74M derived: sum of 2 quarters · filed 2017-05-01 | $29.77M derived: sum of 3 quarters · filed 2017-05-01 | $31.50M derived: sum of 4 quarters · filed 2017-05-01 |
| 2016-01-01 | $21.98M 10-K · filed 2018-02-26 | |||
| 2015-12-31 | $6.56M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $18.58M derived: sum of 2 quarters · filed 2017-02-27 | $20.32M derived: sum of 3 quarters · filed 2017-02-27 | $21.98M 10-K · filed 2017-02-27 |
| 2015-09-30 | $12.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $13.76M derived: sum of 2 quarters · filed 2016-11-03 | $15.42M 10-Q · filed 2016-11-03 | $16.97M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-06-30 | $1.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $3.39M 10-Q · filed 2016-08-03 | $4.95M derived: sum of 3 quarters · filed 2017-02-27 | $5.66M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-03-31 | $1.66M 10-Q · filed 2016-05-04 | $3.21M derived: sum of 2 quarters · filed 2017-02-27 | $3.93M derived: sum of 3 quarters · filed 2017-02-27 | $7.91M derived: sum of 4 quarters · filed 2017-02-27 |
| 2014-12-31 | $1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $2.27M derived: sum of 2 quarters · filed 2017-02-27 | $6.25M derived: sum of 3 quarters · filed 2017-02-27 | $10.01M 10-K · filed 2017-02-27 |
| 2014-09-30 | $714.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $4.70M derived: sum of 2 quarters · filed 2015-11-10 | $8.45M 10-Q · filed 2015-11-10 | $11.98M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $3.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | $7.74M 10-Q · filed 2015-08-11 | $11.27M derived: sum of 3 quarters · filed 2016-02-29 | $14.17M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $3.76M 10-Q · filed 2015-04-30 | $7.29M derived: sum of 2 quarters · filed 2016-02-29 | $10.18M derived: sum of 3 quarters · filed 2016-02-29 | $13.11M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $3.53M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $6.43M derived: sum of 2 quarters · filed 2016-02-29 | $9.35M derived: sum of 3 quarters · filed 2016-02-29 | $12.03M 10-K · filed 2016-02-29 |
| 2013-09-30 | $2.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $5.82M derived: sum of 2 quarters · filed 2014-11-04 | $8.50M 10-Q · filed 2014-11-04 | $11.11M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-06-30 | $2.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $5.61M 10-Q · filed 2014-07-31 | $8.22M derived: sum of 3 quarters · filed 2015-03-02 | $10.12M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-03-31 | $2.68M 10-Q · filed 2014-05-01 | $5.29M derived: sum of 2 quarters · filed 2015-03-02 | $7.19M derived: sum of 3 quarters · filed 2015-03-02 | $9.18M derived: sum of 4 quarters · filed 2015-03-02 |
| 2012-12-31 | $2.61M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $4.51M derived: sum of 2 quarters · filed 2015-03-02 | $6.50M derived: sum of 3 quarters · filed 2015-03-02 | $8.83M 10-K · filed 2015-03-02 |
| 2012-09-30 | $1.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30 | $3.89M derived: sum of 2 quarters · filed 2013-10-30 | $6.22M 10-Q · filed 2013-10-30 | $8.91M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-06-30 | $1.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $4.32M 10-Q · filed 2013-08-06 | $7.01M derived: sum of 3 quarters · filed 2014-02-20 | $9.99M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-03-31 | $2.33M 10-Q · filed 2013-05-07 | $5.02M derived: sum of 2 quarters · filed 2014-02-20 | $8.00M derived: sum of 3 quarters · filed 2014-02-20 | $10.83M derived: sum of 4 quarters · filed 2014-02-20 |
| 2011-12-31 | $2.69M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | $5.66M derived: sum of 2 quarters · filed 2014-02-20 | $8.50M derived: sum of 3 quarters · filed 2014-02-20 | $12.10M 10-K · filed 2014-02-20 |
| 2011-09-30 | $2.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $5.81M derived: sum of 2 quarters · filed 2012-11-07 | $9.41M 10-Q · filed 2012-11-07 | $13.78M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-06-30 | $2.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02 | $6.43M 10-Q · filed 2012-08-02 | $10.80M derived: sum of 3 quarters · filed 2013-02-21 | $16.27M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-03-31 | $3.60M 10-Q · filed 2012-05-03 | $7.97M derived: sum of 2 quarters · filed 2013-02-21 | $13.43M derived: sum of 3 quarters · filed 2013-02-21 | |
| 2010-12-31 | $4.37M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $9.83M derived: sum of 2 quarters · filed 2013-02-21 | $21.11M 10-K · filed 2013-02-21 | |
| 2010-09-30 | $5.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $16.74M 10-Q · filed 2011-10-27 | ||
| 2010-06-30 | $11.28M 10-Q · filed 2011-08-04 | |||
| 2009-12-31 | $22.91M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |